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ABSTRACT 
Background: This study assessed the sociodemographic, medical and psychological 
predictors of accuracy of perceived risk in women at increased genetic risk for ovarian cancer.    
Methods: Women participating in a large cohort study who were at increased risk of ovarian 
and fallopian tube cancer, had no personal history of cancer and had >1 ovary in situ at cohort 
enrolment, were eligible. Women completed self-administered questionnaires and attended an 
interview at enrolment.  
Results: Of 2,868 women unaffected with cancer at cohort enrolment, 561 were eligible.  335 
women (59.8%) overestimated their ovarian cancer risk, while 215 women (38.4%) accurately 
estimated their risk, and 10 (1.8%) underestimated it. Women who did not know their 
mutation status were more likely to overestimate their risk (OR 1.74, 95% CI 1.10, 2.77, 
p=0.018), as were those with higher cancer-specific anxiety (OR 1.05, 95% CI 1.02, 1.08, 
p<0.001) and/or a mother who had been diagnosed with ovarian cancer (OR 1.98, 95% CI 
1.23, 3.18, p=0.005).  Amongst the group of women who did not know their mutation status, 
63.3% overestimated their risk and the mean perceived lifetime risk of developing ovarian 
cancer was 42.1%, compared to a mean objective risk of 6.4%.   
Conclusions:  A large number of women at increased risk for ovarian cancer overestimate 
their risk.  This is of concern especially in women who are at moderately increased risk only; 
for this sub-group of women, interventions are needed to reduce potentially unnecessary 
psychological distress and minimise engagement in unnecessary surgery or screening.  
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Ovarian cancer is not highly prevalent, however it is associated with high mortality with a 5-
year survival rate of 40% [1]. Approximately 15% of invasive ovarian cancers are due to an 
inherited predisposition [2, 3]}.Women with a family history of breast and/or ovarian cancer 
are at significantly increased risk for ovarian cancer, as are women from families with 
hereditary non-polyposis colorectal cancer.  Women who are carriers of germline mutations in 
the breast/ovarian cancer susceptibility gene, BRCA1, are estimated to have a lifetime risk of 
ovarian cancer of about 40% [4], while mutations in the second breast/ovarian cancer 
susceptibility gene, BRCA2, and those related to hereditary non-polyposis colorectal cancer, 
are associated with a lifetime risk of about 10% [4, 5]. Given that the lifetime risk of ovarian 
cancer is approximately 1% in the female population [6], women from families affected by 
these hereditary cancer syndromes are at greatly increased risk of ovarian cancer.  
 
It is now recognised that fallopian tube and primary peritoneal carcinomas are histologically 
and clinically identical to invasive serous epithelial ovarian cancer and have a common 
embryological origin, with many now considered to be derived from the fimbria of the 
fallopian tubes [7]. However for the sake of brevity, this group of cancers will be referred to 
as ‘ovarian cancer’ hereafter, although arguably the term ‘ovarian cancer’ is misleading and 
the best terminology is being debated at present.  
 
Little is known about the accuracy of ovarian cancer risk perception in women at increased 
genetic risk of developing ovarian cancer. To date, two studies have measured the accuracy of 
ovarian cancer risk perception in women with a family history of the disease [8, 9], and in 
BRCA1 and BRCA2 carriers prior to risk-reducing oophorectomy [10]. In a familial ovarian 
cancer clinic setting, women were more likely to underestimate (44%), than overestimate 
(10%) their ovarian cancer risk; 37% were accurate in their risk perception [8]. In contrast, 
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from a sample of 117 women attending a familial ovarian cancer screening clinic, women 
were more likely to accurately estimate their risk (56%), compared to 27% and 17% who 
overestimated or underestimated their ovarian cancer risk, respectively [9]. Amongst BRCA1 
carriers, 38% correctly estimated their risk, while 47% overestimated and 16% 
underestimated their risk. A similar proportion (37%) of BRCA2 carriers accurately estimated 
their ovarian cancer risk; however the majority (61%) overestimated, with only 2% of women 
underestimating, their risk [10]. None of these previous studies assessed the 
sociodemographic, medical and psychological predictors of accuracy of perceived risk.   
 
Greater knowledge of accuracy of risk perceptions is important because of the known 
influence of perceived risk on health beliefs and health behaviours.  For example the Health 
Belief Model, the Transactional Model of Stress and Coping and Self-Regulation Theory, all 
emphasise perceived risk or susceptibility as a key dimension underlying uptake of screening 
recommendations and preventative behaviours [11-14]. Studies that examined the influence of 
breast cancer risk perception on uptake of recommended screening have been inconsistent, 
suggesting that women who overestimate their risk both under- and overutilise recommended 
screening [15-17]. In contrast, high perceived ovarian cancer risk is associated with increased 
uptake of ovarian cancer screening [18, 19]. This is particularly concerning given the 
ineffectiveness, both singly and in combination, of current screening methods to detect early 
ovarian cancer and the potential of these to cause harm [20-22].   
 
Heightened perceived risk for ovarian cancer is also associated with uptake of risk-reducing 
salpingo-oophorectomy among women who underwent genetic testing for BRCA1 and BRCA2 
mutations [19]. Given that risk-reducing salpingo-oophorectomy significantly reduces the 
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incidence of ovarian cancer and associated mortality [23, 24], heightened risk perceptions 
may represent a powerful incentive for women to adopt this effective preventative strategy. 
This potential benefit, however, must be considered within the context of the psychological 
burden associated with heightened risk perceptions.  Conversely, women who underestimate 
their ovarian cancer risk may not consider risk-reducing surgery, although their objective risk 
may warrant consideration of such an option. 
 
The sociodemographic, medical and psychological predictors of accuracy of perceived risk in 
women at increased risk for ovarian cancer based on family history are unknown.  This study 
fills the existing gap in the literature by examining a cohort of women from a large registry of 
multiple-case breast and ovarian cancer families.  We hypothesise that accuracy of perceived 
risk will be predicted by: the number of close relatives with ovarian cancer, knowledge of 
one’s BRCA1 and BRCA2 mutation status, diagnosis of one’s mother and/or sister with 
ovarian cancer and increased cancer-specific anxiety.  
 
METHODS 
Sample 
Unaffected women participating in two components (the Clinical Follow-up study and the 
Psychosocial study [25]) of a large epidemiological and clinical study of multiple-case breast 
cancer families from Australia and New Zealand (the Kathleen Cuningham Foundation 
Consortium for Research into Familial Breast Cancer - kConFab), formed the study sample 
[26, 27]. All participants gave their informed consent prior to inclusion into the study. 
Families were recruited after the index family member attended a consultation at one of 16 
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family cancer clinics (FCC). Eligibility criteria for families were complex, but included a 
strong family history of breast cancer and/or ovarian cancer, or a documented BRCA1 or 
BRCA2 mutation [26, 27]. Blood was drawn for potential mutation analysis at enrolment 
(although only key individuals in each family were actually tested initially) and epidemiology 
and family history questionnaires were completed. Unless the individual had already attended 
an FCC, genetic counselling was not required before research-based genetic testing. When a 
BRCA1 or BRCA2 mutation was found in the index family member, all enrolled family 
members who had previously indicated they would like to receive such information were 
notified that relevant genetic information had become available and were invited to attend a 
FCC for genetic counselling and personal genetic testing for the family mutation. Overall 
41.2% of individuals attended a familial cancer clinic for genetic testing [28].    
 
Longitudinal follow-up and psychosocial data were collected in parallel using three-yearly 
self-report questionnaires and a semi-structured interview [25]. Cancer events, risk 
management practices, epidemiological and lifestyle risk factors, cancer risk perception, 
psychological variables, personality characteristics, levels of social support and life-event 
stress were updated every three years.  The analysis reported here describes data collected at 
cohort entry only. 
 
To be eligible for the current analysis, women had to have no personal history of cancer 
(except non-melanoma skin cancer or cervical intraepithelial neoplasia CIN I-III) at the time 
of enrolment, have at least one ovary in situ at the time of cohort enrolment and be at 
increased risk for ovarian cancer (i.e. carry a BRCA1 or BRCA2 mutation and/or have at least 
one first- or second-degree relative with ovarian cancer).  Women who were found to be non-
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carriers of the BRCA1 or BRCA2 mutation segregating in their family and knew their mutation 
status at cohort entry were excluded from analyses.  
 
Measures 
Predictor variables 
Demographics: Age, educational level (university-educated or high school-educated), marital 
status and parity at enrolment were collected at interview.   
Family history: Total number of first- and second-degree relatives diagnosed with ovarian 
cancer, and whether the woman’s mother or (at least one of) her sister/s died from ovarian 
cancer at enrolment were recorded and verified where possible.   
Genetic testing results: Women’s genetic test results (for those in whom a mutation was 
identified in their family) were based on kConFab records rather than self-report.  
Participants’ knowledge of their mutation status was determined during the psychosocial 
interview and verified, where possible, from kConFab records.  Whether a woman had 
attended a familial cancer clinic was ascertained as part of the Clinical Follow-Up study.  
Cancer-specific anxiety: This was assessed using the seven-item Intrusive Thoughts subscale 
of the Impact of Event Scale (IES) [29]. Intrusion was defined as ‘the involuntary entry into 
awareness of ideas, memories and emotions.’ Specifically, participants were asked about the 
frequency and severity of intrusive thoughts about being at risk of developing breast /ovarian 
cancer in the past week, ranging from ‘Not at all’ to ‘Often’. Scores ranged from “0-35”, with 
higher scores indicating more intrusive thoughts [30]. Internal consistency (Cronbach’s 
α=0.88) and test-retest reliability (r=0.75) of this subscale have been reported previously in 
high-risk women [31].  
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Dispositional Optimism: The Life Orientation Test (LOT) was included to assess 
dispositional optimism.  It is a widely used questionnaire with well-documented psychometric 
properties [32]. Scores range from 0 to 32, with higher scores indicating more optimism.  
Social support: This was assessed by the Duke-UNC Functional Social Support Questionnaire 
[33]. This 8-item scale is a validated measure of the degree of satisfaction with available 
support. Scores range from 8 to 40, with higher scores indicating more social support.  
Perceived lifetime risk of developing ovarian cancer: This was assessed by asking 
participants to indicate their perceived risk on a numerical differential scale ranging from 0 
(‘No chance’) to 100 (‘Definitely’). This item has been used previously in similar studies 
[34].  
Objective lifetime risk of developing ovarian cancer: At cohort entry, objective lifetime risk 
was calculated using the Breast and Ovarian Analysis of Disease Incidence and Carrier 
Estimation Algorithm (BOADICEA), which can be used to estimate the risks of developing 
ovarian cancer by age 70. The algorithm is based on segregation analysis of breast and 
ovarian cancer occurrence in a population-based series of 1484 breast cancer cases and 156 
multiple case families from the United Kingdom [35].  
 
Outcome variable 
Accuracy of perceived risk: Accuracy of perceived risk was determined by comparing a 
woman’s objective lifetime risk according to BOADICEA to her perceived risk of developing 
ovarian cancer. If the woman’s objective lifetime risk was within ±25% of her perceived risk, 
she was categorised as accurately perceiving her risk; and if it was more than 25% below or 
above her objective risk she was categorised as an underestimator or overestimator 
respectively.   
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Statistical analysis 
Data were initially explored with descriptive statistics. The continuous predictor variables, 
cancer-specific anxiety, total number of relatives diagnosed with ovarian cancer, and social 
support were non-normally distributed; Kruskall-Wallis tests were used in the bivariate 
analyses of these variables. The continuous predictor variables age and optimism were 
normally distributed; ANOVA tests were used in the bivariate analyses of these variables. To 
explore the associations between the categorical predictor variables (marital status, education, 
country of birth, parity, mutation status, sister or mother diagnosed with ovarian cancer) and 
the binary perceived risk variable, Pearson chi square tests was used.   
 
 As there were only a very small number of underestimators (N=10, 1.8%), this group was not 
included in the logistic regression due to insufficient power. Covariates with p<0.25 in 
bivariate analyses were entered into a logistic regression [36].  A progressive backward 
elimination modelling strategy was used until a final model was obtained containing only 
variables with p<0.05.  
 
Results 
This study was undertaken as part of a larger study, which also assessed the psychological 
factors associated with uptake of risk-reducing salpingo-oophorectomy [37].  Of the entire 
sample of 2,868 unaffected women included in both the kConFab Psychosocial and Clinical 
Follow-Up studies, the final sample consisted of 561 women, who met all the eligibility 
criteria for this current analysis.  The vast majority of ineligible women (2,054) were 
ineligible because they did not have an increased risk of ovarian cancer.  See Figure 1 for a 
description of establishing the final sample size.    
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[Insert Figure 1 about here] 
 
Table 1 describes the baseline characteristics of the sample.  The mean age of the sample was 
42.8 years (standard deviation, 12.4 years). 411 (73.3%) women were parous.  The median 
number of first- and second-degree relatives diagnosed with ovarian cancer was one (range 0-
12).  Of the 561 women included in this study, 145 (25.8%) had a mother diagnosed with 
ovarian cancer, while 56 (10.0%) reported a sister diagnosed with ovarian cancer. In terms of 
knowledge of mutation status, 119 (25%) reported having had genetic testing and having been 
informed of their mutation positive result, while 353 (75%) reported not having had genetic 
testing; the reason for non-testing are not known. Two hundred and thirty-one (41.2%) 
women reported having attended a familial cancer clinic. Three hundred and thirty-five 
women (59.8%) overestimated their ovarian cancer risk, while 215 women (38.4%) accurately 
estimated their risk, and 10 (1.8%) underestimated ovarian cancer risk.  
 [Insert Table 1 about here] 
Table 2 shows the percentages of underestimates, accurate estimators and overestimators for 
each of the categorical predictor variables including the results of bivariate analyses, while 
Table 3 shows the same data for each of the continuous variables.  Table 2 shows that, 
amongst women who did not know their mutation status, 63.3% overestimated their risk, 
compared to 47.1% who were tested and were aware they were carriers.  Additional analyses 
(not shown) showed that 23.4% of women who did not know their mutation status 
overestimated their actual lifetime by more than 50%.  Amongst the group of women who did 
not know their mutation status, the mean perceived lifetime risk of developing ovarian cancer 
was 42.1% (SD 25.9), compared to a mean objective risk of 6.4% (SD 11.8).   
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[Insert Tables 2 and 3 about here] 
 
Table 4 summarises the results of the logistic regression. Women who did not know their 
mutation status were more likely to overestimate their risk (OR 1.74, 95% CI 1.10, 2.77, 
p=0.018), as were those with higher cancer-specific anxiety (OR 1.05, 95% CI 1.02, 1.08, 
p<0.001) and/or a mother who had been diagnosed with ovarian cancer (OR 1.98, 95% CI 
1.23, 3.18, p=0.005) were more likely to overestimate their risk. 
 
[Insert Table 4 about here] 
 
Discussion 
Our study aimed to explore the sociodemographic, medical and psychosocial predictors of 
accuracy of ovarian cancer perceived risk. Most of our hypotheses were confirmed in that 
women who did not know their mutation status, had a mother who was diagnosed with 
ovarian cancer and those with higher levels of cancer-specific anxiety were more likely to 
overestimate their lifetime risk of ovarian cancer.   
 
Compared to the published literature on the accuracy of risk perception for ovarian cancer, 
our study encountered the largest proportions of misperceptions, with most women (59.8%) 
overestimating their risk of ovarian cancer by 25% or more. By contrast, only 1.8% 
underestimated their risk, while 38.4% were accurate in their risk perceptions.  
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Our finding that women who knew their mutation status were less likely to overestimate their 
ovarian cancer risk, compared to those who did not know their mutation status, is reassuring.  
It underscores that learning one’s mutation carrier risk helps clarify women’s risks of ovarian 
cancer, resulting in more accurate perceived ovarian cancer risk, which in turn may lead to 
less cancer-specific anxiety and other psychological benefits, apart from facilitating improved 
decision-making regarding women’s risk management options.  Amongst women who did not 
know their mutation status, the mean perceived lifetime risk was 42.1%, compared to a mean 
actual risk of 6.5%, indicating that many of these women (many of whom were at only 
moderately increased risk for ovarian cancer), vastly overestimated their risk as being similar 
to the risks for BRCA1 mutation carriers.  For intervention planning, it would be important to 
identify women who are at only moderately increased risk and who overestimate their ovarian 
cancer risk. Overestimators may be at significantly increased risk of cancer-specific anxiety 
and other psychological distress. They may also be at increased risk of making decisions 
regarding risk-reducing salpingo-oophorectomy primarily motivated by anxiety rather than an 
accurate understanding of their objective risk or be participating unnecessarily in ovarian 
cancer screening because of their inaccurate risk perceptions.  
 
Our analysis showed that women who had a mother diagnosed with ovarian cancer were more 
likely to overestimate their risk of developing ovarian cancer. Our other hypothesis that 
overestimation of risk would be associated with the total number of first- and second-degree 
relatives and having a sister diagnosed with ovarian cancer was not confirmed.  The impact of 
having a mother who was diagnosed with ovarian cancer on perceived risk reflects both 
experiential and objective factors. Heightened risk perceptions may develop as a result of 
vicariously living the cancer experience through a relative, particularly if there is a close 
relationship [38]. Experiencing a mother’s breast cancer and/or death and/or having acted as 
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her caregiver have been shown to be a psychological risk factors for women at high risk for 
breast and ovarian cancer [31]. Thewes et al. interpret this observation in the context of 
attachment theory, which posits that temporary or permanent loss of the primary attachment 
figure is frequently accompanied by grief, anxiety and mourning [31].  Consequently, the 
diagnoses of other close relatives (e.g. sisters) might not have the same potential to increase 
women’s perceptions of their own vulnerability.  In terms of objective factors, women may 
conclude there is a shared genetic inheritance with one’s mother that increases their risk of 
developing cancer; unaffected women are at significantly higher risk of developing ovarian 
cancer even if they have just a single first-degree relative who was diagnosed with ovarian 
cancer at a young age [39]. The experience of having a mother with ovarian cancer and 
recognizing the implications this may have on one’s own risk may arouse significant concern 
in unaffected women, leading to overestimation of risk of developing ovarian cancer. 
 
We also found that higher levels of cancer-specific anxiety were associated with risk 
overestimation. Previous research has shown that there is a consistent association between 
heightened perceived risk of breast cancer and worry or anxiety [40]. Results from our study 
support these findings; women who had higher cancer-specific anxiety were more likely to 
overestimate their risk of ovarian cancer.  High levels of anxiety and/or perceived risk also 
influenced decisions regarding risk-reducing surgery for women at high risk of hereditary 
breast/ovarian cancer [41, 42]. Furthermore, anxiety about breast cancer may interfere with 
comprehension of risk information [43], suggesting that women with high levels of anxiety 
may benefit from anxiety reduction techniques and supportive counselling to normalise 
anxiety levels and enable risk information to be communicated effectively. A number of 
studies have shown that interest in risk-reducing salpingo-oophorectomy in women with a 
family history of ovarian cancer was motivated by a desire to reduce anxiety [44, 45] and was 
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associated with cancer anxiety rather than objective cancer risk [34]. Given the large numbers 
of women in this study who overestimated their ovarian cancer risk and the relationship with 
cancer-specific anxiety, this is of concern. However, Meiser et al. (1999) found no 
statistically significant association between psychological factors including cancer-specific 
anxiety and actual uptake of risk-reducing salpingo-oophorectomy in the same sample of 
women [37]. Nevertheless it is important to be aware that women with inaccurate risk 
perceptions may be at risk of making significant health behaviour decisions based on cancer 
anxiety rather than objective risk. Women who have higher cancer-specific anxiety may 
benefit from interventions designed to correct misperceptions of ovarian cancer risk, e.g. 
communication aids specifically developed for use in cancer genetic counselling to facilitate 
communication of breast and/or ovarian cancer risk [46].  
 
Our regression analyses showed that overestimation of risk was unrelated to women’s ages.  
This is in contrast to previous studies, which have found that perceived lifetime risk was 
inversely related to age [47].  In clinical practice provision of age-specific risks (e.g. risk over 
the next 10 years) is very important, given that risk management decisions will be influenced 
by the magnitude of risks at varying ages, in addition to being impacted by childbearing 
decisions and consideration of the risks of menopausal and sexual symptoms, which in turn 
are also age-dependent.  This study only assessed women’s perceived lifetime risks for 
ovarian cancer; given the importance of age-specific risks, future studies should ask women 
about perceived age-specific risks.   
 
The other limitations of our study should be noted.  About 60% of women in our sample had 
had no direct contact with a familial cancer clinic and as a result had not received genetic 
 16 
counselling nor specialist risk management advice regarding their family history and/or risk 
of developing ovarian cancer. Without accurate or personalized risk information, women may 
have been much more likely to overestimate their ovarian cancer risk. We did not elicit why 
women were not tested, which could have been due to personal choice, because they did not 
understand where to go for testing, or because testing was unavailable. These different groups 
may well have different subjective risk perceptions that were obscured by pooling them here.  
Historically it has been difficult to accurately estimate women’s ovarian cancer risks, and risk 
estimation remains a clinically fraught area. The BOADICEA model used in this paper has 
been validated for breast cancer risk [35, 48], but not for ovarian cancer risk. However due to 
the lack of established ovarian cancer risk data, it remains the ‘gold standard’. Other studies 
in this area have used different published estimates of objective risk for ovarian cancer [4, 49, 
50] , as well as different measures for misperception, which makes comparison between 
findings challenging.  
 
Conclusion 
Our study contributes to the growing literature on the accuracy of perceived risk in women at 
increased risk of ovarian cancer. In our large sample of unaffected women at increased risk of 
ovarian cancer, the majority of women overestimated their risk of developing ovarian cancer. 
It is important to identify women who overestimate cancer risk to potentially reduce 
unnecessary psychological distress, and minimise engagement in unnecessary surgery, 
especially in women whose objective risk is only moderately increased.  Clinicians should be 
particularly attuned to the possibility of overestimation of ovarian cancer risk by women who 
have a mother diagnosed with the disease. Greater understanding of the associations between 
perceived risk, psychosocial characteristics and health behaviours is important so that risk 
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assessment and risk management can be targeted to those most at risk of cancer risk 
misperceptions. Genetic counselling is effective in increasing the accuracy of risk perceptions 
[41, 51, 52] and may be important in providing information tailored to the individual about 
hereditary cancer risks, facilitating adaptation to personal risk, and enabling informed 
decisions about risk management options.  
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Table 1.  Baseline sample characteristics (N=561)a 
Characteristics N (%) 
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OvCa = Ovarian cancer; FDR = First-degree relatives with ovarian cancer; SDR = Second-degree 
relatives with ovarian cancer. a = Cell frequencies vary due to missing data for some variables.  *These 
women are true mutation negatives (according to the research genetic testing result) but may have 
chosen not to have clinical testing, so would be unaware they are mutation negative. 
Age  
Mean (SD) 42.8 (12.4) 
<30 
30-39 
40-49 
50-59 
60-69 
70+ 
 
 
76 (13.7) 
162 (29.2) 
153 (27.6) 
99 (17.8) 
55 (10.6) 
6 (1.1) 
Marital status  
Married/living as married 
Widowed/single/divorced 
 
400 (73.1) 
147 (26.9) 
Parity 
Has children 
Does not have children 
 
411 (73.4) 
149 (26.6) 
Educational level 
No university education 
University graduate 
 
439 (79.2) 
115 (20.8) 
Country of birth 
Australia 
New Zealand 
United Kingdom 
Other 
 
453 (80.7) 
53 (9.4) 
29 (5.2) 
26 (4.6) 
Total number of FDR and SDR with OvCa 
0 
1 
2 
3+ 
 
77 (13.8) 
375 (67.1) 
84 (15.0) 
23 (4.2) 
Research genetic mutation status 
BRCA1/2 mutation positive 
BRCA1/2 mutation negative* 
No mutation identified in family 
 
177 (31.6) 
163 (29.1) 
220 (39.3) 
Knowledge of mutation status 
Individual tested and informed mutation positive 
Individual either not tested or no mutation identified in family  
 
119 (25.2) 
353 (74.8) 
Attended familial cancer clinic 
               Yes 
               No 
 
231 (49.5) 
236 (51.2) 
Mother cancer status 
Diagnosed with OvCa 
Not diagnosed with OvCa 
 
145 (25.8) 
416 (74.2) 
Sister cancer status 
Diagnosed with OvCa 
No sister or sister not diagnosed with OvCa 
 
56 (10.0) 
505 (90.0) 
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Table 2.  Bivariate analyses of accuracy of perceived risk for categorical predictor variables 
 
χ2 = chi square test statistic; * entered into regression model; OvCa = ovarian cancer; a = Cell frequencies vary 
from Table 1 due to missing data for accuracy of risk variable.  
 
 
 
 
 
 
 
 
 Accuracy of perceived risk 
Predictor variables 
  
Underestimator 
(N=10) 
Accurate estimator 
(N=215) 
Overestimator 
(N=335) 
  
 N % N % N % χ2 p 
Marital statusa 
Married/ living as married  
Not married/living as married 
 
6 
4 
 
1.5 
2.7 
 
160 
48 
 
40.1 
32.7 
 
233 
95 
 
58.4 
64.6 
 
3.13 
 
0.21* 
Education  
University graduate 
Not a university graduate 
 
2 
8 
 
1.7 
1.8 
 
48 
164 
 
41.7 
37.4 
 
65 
266 
 
56.5 
60.7 
 
0.71 
 
0.70 
Childrena 
Has children 
Does not have children 
 
4 
6 
 
1.0 
4.0 
 
157 
58 
 
38.3 
38.9 
 
249 
85 
 
60.7 
57.0 
 
5.95 
 
0.05* 
Knowledge of mutation status 
Individual tested and informed  
mutation positive 
Individual either not tested or not  
informed 
 
 
8 
 
2 
 
 
6.7 
 
0.6 
 
 
55 
 
126 
 
 
46.2 
 
35.8 
 
 
56 
 
224 
 
 
47.1 
 
63.6 
 
 
22.49 
 
 
<0.001* 
Attendance at a  familial cancer clinic 
Yes 
No 
 
8 
1 
 
3.5 
0.4 
 
96 
92 
 
41.6 
39.0 
 
127 
143 
 
55.0 
60.6 
 
11.61 
 
0.02* 
Family mortality history 
Sister diagnosed with OvCa 
No sister or sister not diagnosed with  
    OvCa 
Mother diagnosed with OvCa 
Mother not diagnosed  
     with OvCa 
 
0 
10 
 
0 
10 
 
0.0 
2.0 
 
0.0 
2.4 
 
21 
194 
 
40 
175 
 
37.5 
38.5 
 
27.8 
42.1 
 
35 
300 
 
104 
231 
 
62.5 
59.5 
 
72.2 
55.5 
 
1.19 
 
 
14.13 
 
0.54 
 
 
0.001* 
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Table 3.  Bivariate analyses of accuracy of perceived risk for continuous predictor variables (N = 561) 
χ2 = Kruskal-Wallis test statistic; F = ANOVA test statistic; FDR = First-degree relatives with ovarian cancer; 
SDR = Second-degree relatives with ovarian cancer; * = Entered into regression model; 
 
 
 
 
 
 
 
 
 
 
 
 
 Accuracy of perceived risk   
Predictor variables Underestimator 
(N=10) 
Accurate estimator 
(N=215) 
Overestimator 
(N=335) 
 
  
 Mean SD Mean SD Mean SD   χ2/F p 
Age 37.0 7.8 43.6 12.2 42.4 12.5 1.7 0.18* 
Total number FDR and    
   SDR diagnosed with     
   OvCa 
0.7 0.8 1.1 1.3 1.2 0.9 14.7 0.001* 
Cancer-specific  anxiety 8.3 10.3 5.1 7.2 8.1 8.7 21.5 <0.001* 
Optimism 22.6 6.1 20.8 5.3 19.0 5.7 8.2 <0.001* 
Social support 30.5 8.3 30.9 7.5 29.6 7.8 3.7 0.15* 
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Table 4.  Final regression model of overestimation of perceived risk for ovarian cancer 
Variable  OR* 95%  CI OR p 
    
Knowledge of mutation status  
  No 
               Yes (reference category) 
1.74 1.10, 2.77 0.018 
Cancer-specific anxiety 1.05 1.02, 1.08 <0.001 
diagnosed with ovarian cancer  
Yes 
No (reference category) 
 
1.99 
 
1.24, 3.20 
 
0.004 
    
Note: Final model: -2 Log likelihood = 579.94; χ2 = 27.30; p <0.001; OR = odds ratio 
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Fig1 Description of sample selection from complete psychosocial database 
 
 
 
 
 
 
 
 
 
 
 
Total sample  
(N = 2868) 
Not at increased risk for 
ovarian cancer  (N = 2054) 
 
N = 805 
Had RRSO prior to cohort entry 
 (N = 133) N = 672 
Participant had knowledge at cohort 
entry that she does not carry the family 
mutation  
(N = 95) 
 
N = 577 
Overestimator 
N = 335 
Accurate estimator 
N = 215 
Underestimator 
N = 10 
No objective or perceived risk 
data available 
 (N = 16) 
N = 561 
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